A common cell-type specific surface antigen in cultured human glial cells and fibroblasts: loss in malignant cells by unknown
A  COMMON  CELL-TYPE  SPECIFIC  SURFACE  ANTIGEN 
IN CULTURED  HUMAN  GLIAL CELLS 
AND  FIBROBLASTS:  LOSS IN MALIGNANT  CELLS* 
BY ANTTI  VAHERI,  ERKKI  RUOSLAHTI,  BENGT  WESTERMARK,  AND JAN  PONTI~N 
(From the Department  of Virology and of Serology and Bacteriology,  University of Helsinki, SF- 
00290 Helsinki 29, Finland; and, The Wallenberg Laboratory and Department  of Pathology, 
University  of Uppsala, S-75122 Sweden) 
Previous  studies  have  shown  that  normal  chicken  and  human  fibroblasts 
contain  a  major  cell-type  specific surface antigen  (fibroblast surface  antigen, 
SFA). 1 It  is  a  high  molecular  weight  glycoprotein  (1,  2)  that  is  lost  after 
transformation  by RNA or DNA viruses (3,  4).  Virus-transformed  fibroblasts 
lack surface SFA but produce it to the culture medium.  In normal fibroblasts 
SFA (for summary see reference 5) is mainly located in fibriltar structures of the 
cell surface and in cellular processes (6). Considerable quantities of the antigen 
are also shed from normal cultured fibroblasts and it is also present in circula- 
tion (plasma and serum), presumably as a result of shedding in vivo. Serum SFA 
shows affinity to fibrinogen and fibrin (7) and is identical  with what has been 
known as the "cold insoluble globulin" of human plasma (8). SFA was not found 
in  several  other  cell  types  including  parenchymal  cells  of various  organs, 
lymphocytes, erythrocytes, amnion, lymphoma, and carcinoma cells (1, 2, 9) but 
has been constantly detected in fibroblasts in vivo and in vitro. 
The close functional relationship between fibroblasts and glial cells has led us 
to study the latter cell type for the presence of SFA. Using several characterized 
normal  and malignant  human glial cell lines we now show that cultured glial 
cells have SFA immunologically indistinquishable  from that of fibroblasts and 
that on cell surface it is also distributed to fibrillar processes. The data also show 
that  malignant  glioma lines established from human  tumor patients produce 
SFA but retain little or none on cell surface. 
Materials  and  Methods 
Cells.  All cell lines were grown at 37°C in Eagle's basal medium plus 10% fetal calf serum and 
were regularly subcultured twice a  week using a  solution of 0.25% trypsin and 0.02% EDTA in 
phosphate-buffered saline (PBS) to disperse the cells. 
The  normal  glial  cell  lines have been grown from  explant  cultures of non-neoplastic adult 
human tissue obtained from neurosurgical operations as described by Pont~n and Macintyre (10). 
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The three lines,  MIRI (kindly provided by Dr.  T.  WahlstrSm,  Third Department of Pathology, 
University of Helsinki, Helsinki, Finland), U-787 CG, and U-813 CG represent diploid astroglial 
cells, have an astrocyte-like morphology, a  finite life-span (about 25 cell generations), and a low 
terminal saturation density (Table I and references 11, 12). All experiments have been performed 
on cells in the phase of rapid proliferation [phase II according to Hayflick (13)]. 
The origin of the giioma lines has been described (14).  Some of their properties are given in 
Table I. Because of the absence of spontaneous infinite growth transformation among normal glial 
cells, the infinite life-span of the glioma cells in culture is a reliable criterion on their neoplastic 
origin. Production of the neuroectoderm-specific protein S-100 (16) by some representative lines of 
the panels of normal (K. Haglid, and B. Westermarck, unpublished data) and malignant (17) glial 
lines  is  in  agreement  with  their  glial  origin.  The  origin  of  the  normal  (WI-38)  and  SV40- 
transformed (WI-38/VA-13) human fibroblasts was reported earlier (4). 
Anti-SF Antibodies and Their Specificity.  We have used two types of anti-SF antibodies in 
these  studies  (a)  antibodies  produced  against  fibroblast  surface  SFA  (anti-SF-FIBR)  and  (b) 
antibodies produced against SFA purified from normal human plasma (anti-SF-NHP). For prepa- 
ration of anti-SF-FIBR, digests of extensively washed live fibroblast cultures (MRC-5 line) were 
obtained using brief treatment with matrix-bound papain. The digests were clarified by ultracen- 
trifugation, dialyzed, and used to immunize sheep. After absorption with calf serum (a component 
of the fibroblast growth medium) and with insolubilized iodoacetamide-inactivated papain,  the 
antisera have given a single precipitation line against the immunogen, concentrated supernates of 
spent medium of fibroblast cultures, and against human serum and plasma (2). It is known that 
the monospecificity of such seemingly crude antisera is most probably due to two things: SFA in 
cultured fibroblasts is a major surface component and is highly susceptible to release from the cell 
surface by proteolysis, e.g. by papain, trypsin, and plasmin (references 2 and 3, and footnote 2). To 
ensure specificity for SFA at the level of immunofluorescence and radioimmunoassay the antisera 
have been absorbed extensively with purified human blood leukocytes (gift from Dr.  G. Myllyl/i, 
The  Finnish Red  Cross  Blood  Transfusion  Center,  Helsinki,  Finland) using  100  /~t  of packed 
leukocytes/ml of serum.  For the routine immunofluorescence the IgG fraction of such absorbed 
antisera  was  used  as  such.  To  check  the  specificity of the  immunofiuorescence  tests  anti-SF 
antibodies have been further purified by affinity chromatography. Anti-SF antibodies were bound 
to an immunoadsorbent prepared by conjugating human serum protein (including serum SFA) to 
agarose beads (Sepharose 4B, Pharmacia Fine Chemicals, Inc., Uppsala, Sweden). The beads were 
washed with PBS,  and the bound  antibodies were  eluted with 8 M  urea (18).  The eluate  was 
dialyzed against distilled water and lyophilized. For preparation of anti-SF-NHP, human plasma 
SFA was purified by cryoprecipitation, DEAE-cellulose chromatography, and isoelectric focusing 
(7) and use to immunize rabbits. 
The two types of antibody preparations, anti-SF-FIBR and anti-SF-NHP, reacted identically in 
immunodiffusion tests and in immunofiuorescence against cells or materials derived from them. 
The immunofluorescence reactions were blocked totally by either highly purified plasma SFA, 
papain digests of fibroblast cultures, or with normal human serum but not by bovine or chicken 
serum. 
Immunofluorescence.  Confluent cultures were seeded in a  1:4 ratio, grown on cover slips, and 
used  at  1-day old.  For total  immunofluorescence the  cover slip cultures  were fixed  with 3.5% 
HCHO and acetone and then stained.  For surface immunofiuorescence the cultures were rinsed 
with ice-cold PBS, stained at  ±0°C and then fixed (HCHO also at ±0°C).  With anti-SF-FIBR we 
used  direct  and  with  anti-SF-NHP  indirect  immunofluorescence  as  described  in  more  detail 
elsewhere (4). 
Papain Digests of  Glial Cells and Antiglial Papain Digest Antisera.  These were prepared using 
the  U-813  CG cell line and the  procedures  described above and those described previously  for 
human fibroblast SFA. 
Solubilization of Cellular  SFA.  Cellular  SFA  was solubilized in  antigenically  active  form 
using a  solution containing 8 M urea,  1% Triton X-100, 0.02% NAN3, and 1 mM phenylmethylsul- 
phonylfluoride (3). 
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TABLE  I 
The Glia-Glioma  System 
Cell line  Morphology 
Population 
doubling 
time in 10~ 
calf serum 
Terminal sat- 
uration den- 
sity (×  10  -~ 
cells/cm  2) in 
10~ calf se- 
rum 
Normal astroglia 
U-787 CG  Astrocyte like 
U-813 CG 
MIRI 
Malignant astrocytomas 
U-105 MG  Astrocytoid 
U-118 MG  Bipolar, spindle 
U-251 MG  Bipolar, spindle 
U-343 MG  Polygonal, spindle 
U-343 MG-a*  Polygonal, spindle 
h 
24 -30  50 -90 
49  480 
33  220 
35  550 
31  360 
31  360 
References 12,  14, and 15 
* A subline of U-343 MG isolated by explantation on a  feeder layer of normal glia. 
Radioimmunoassay (RIA).  A double antibody RIA (18) using 12~I-SFA purified from serum (7) 
has been used. The reaction mixture in the assay consisted of 900 pl of PBS plus 0.2% bovine serum 
albumin, 100 ~l of the sample (or standard) diluted in urea-Triton X-100,  100 ~l of ~2'~I-SFA (19) 
duluted in PBS plus 0.2% bovine serum albumin, and 100 tzl of a suitable dilution of anti-SFA. 
Results 
Glial Cells Contain SFA.  Papain-released material and urea-Triton X-100 
extracts from human glial cell cultures contained an antigen indistinquishable 
from the fibroblast SFA in immunodiffusion (Fig.  1).  Antiserum produced by 
immunizing with papain digest from glial cell cultures showed only antibodies 
which reacted with fibroblast extracts, normal human serum, and SFA purified 
from human plasma. 
Localization  of SFA in Normal Glial Cells.  In cultures of normal human 
glial  cells,  fixed  with  formaldehyde and  acetone,  all  cells  stained  strongly 
positive in immunofluorescence with anti-SFA antibodies. Two types of fluores- 
cence  were  seen:  (a)  a  fibrillar type  of fluorescence that  often had  a  radial 
pattern (Fig. 2).  It extended to the cellular processes, was present also on the 
growth substrate (the cover slip), and on the extracellular space outside the cell 
body. The radially orientated "SFA striae" were absent on the blunt side of the 
cell. (b) Strong "microgranular" SFA fluorescence that is predominantly located 
in the perinuclear area was seen intracellularly. When glial cells were stained 
for surface SFA by anti-SFA-antibodies at -+ O°C and then fixed only the fibrillar 
type of fluorescence was seen (Fig. 3). 
Localization of SFA in Glioma Cells.  In three glioma lines (U-118  MG, U- 
251  MG,  and  U-343 MG-a)  no  or  very little SFA  was detected in  the  great 
majority (>95%)  of the cells  (like the three negative or weakly positive cells 
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FIG.  1.  Immunodiffusion in agarose.  (1) Normal human serum.  (2) Papain digest from 
glial cells. (3) Papain digest from fibroblasts. (4) Urea-Triton X-100 extract from glial cells. 
(5) Urea-Triton X-100 extract from fibroblasts. (6) Papain 100/zg/ml. Center well: anti-SF 
antiserum (absorbed with insolubilized papain and calf serum). 
FIG.  2.  Normal human glial cell (line U-787 CG) fixed with formaldehyde and acetone and 
stained  by  immunofiuorescence  utilizing anti-SF antibodies.  Note  presence  of SFA in 
radially oriented striae and in the perinuclear area of the cytoplasm. × 750. 
cells and line U-105 MG was clearly positive, showing both intracellular  granu- 
lar fluorescence and  SFA-containing  fibrillar striae (Fig.  5).  However,  even in 
these cells the intensity of SFA fluorescence was less than  that  seen in normal 
glial cells. 
A  small  fraction of cells in  several of the  cultured  glioma  lines were  inten- 
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FIG.  3.  Surface SFA in normal glial cell (line U°813 CG). Live cell cultures were stained 
by immunofluorescence  in the cold and were then fixed. Note SFA striae in cell periphery. 
Some nonspecific autofluorescence may be seen in the nucleus. ×  750. 
cence and in many cases two nuclei (Figs. 4 and 6) suggesting that they were in 
the telophase stage of the cell cycle. 
When cultures ofglioma cells were stained by immunofluorescence for surface 
SFA,  lines  U-118  MG,  U-251  MG,  and  U-343  MG-a  were  negative.  Weak 
irregular SFA-containing striae were seen in cells of the U-105 MG line and very 
faintly in some cells of the U-343 MG line. 
Quantitation of SFA in Cells and Growth Media.  The concentration of SFA 
in the cells and the medium  2 days after subculture is given in Table II.  The 
results were essentially similar on day 1 and day 3. The concentration of SFA in 
normal  glial cells exceeds that  in normal  fibroblasts and is much higher than 
that in malignant  glial cells. In the latter group the concentration  was highest 
in cells of line U-105 MG (Table II), in agreement with the results of immunofluo- 
rescence  experiments.  Both  normal  and  malignant  glial  cells  produce  SFA. 
When plotted against the amount of cell-associated protein present at the time 
of harvesting  the total  amount  (cells plus medium)  present  in the  malignant 
cultures was between 1 and 30% of that in cultures of normal glial cells. 
Discussion 
The  present  results  show that  human  fibroblasts  and  glial  cells  (astroglia) 
share  a  cell surface antigen,  SFA, which has not been found in other types of 
human cells (2). The concentration of SFA per milligram protein is about two to 
three times higher in cultured glial cells than in fibroblasts. In SFA immunofluo- 
rescence all glial cells uniformly stained strongly positive. In analogy with these 
findings it has been shown that while chicken fibroblast SFA is not detected in 
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F1a.  4.  Giioma cells (line U-343 MG-a) fixed and stained by immunofluorescence. Note 
staining for SFA in the telophase cell in the lower right corner of the figure. The three other 
cells show faint cytoplasmic staining of SFA. × 750. 
Fro.  5.  Glioma cells (line U-105 MG) fixed and stained by immunofluorescence. Note SFA 
as granules in the cytoplasm and as irregularly oriented striae in cell periphery. ×  750. 
Fla.  6.  A  binucleated (telophase ?)  glioma cell (line  U-118  MG)  fixed and  stained by 
immunofluorescence. Note SFA as intensively staining granules in the cytoplasm. Most 
cells in the culture showed very little or no SFA by immunofluorescence.  × 750. 
astroglia morphology are strongly positive for chicken SFA  in immunofluores- 
cence (unpublished  data). 
The  presence  of  SFA  in  fibroblasts  and  glial  cells  but  not  in  other  cells 
suggests that  SFA may  be associated with their functional similarities such as 
the  presence  of cytoplasmic extensions,  strong  mobility,  or role as  supportive 
cells  (20).  Presence  of  SFA  does  not  appear  to  be  an  expression  of  a  close 
ontogenic relationship  since glial cells originate  from  neuroectoderm,  whereas 
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TABLE II 
Radioimmunoassay of SFA in Cells and Growth Media of Normal and 
Malignant Glial Cell Cultures 
Growth medium, 
Cell culture  Cell extract, SFA,  SFA ~g/mg protein 
~g/mg protein  in cell extract 
Normal glia 
U-787 CG  58.4  332.6 
U-813 CG  81.6  391.3 
MIRI  71.7  482.3 
Malignant glia 
U-105 MG  10.9  118.3 
U-118 MG  8.8  108.5 
U-251 MG  0.7  31.3 
U-343 MG  0.4  2.9 
U-343 MG-a  0.3  12.9 
Normal fibroblast 
WI-38  25.2  88.2 
Transformed fibroblast 
WI-38/VA13  2.8  59.6 
Confluent cultures were subcultured in a 1:2 ratio using 5 ml of medium per 20 cm  2. 2 
days later,  when  the cultures were still growing,  supernates of the medium and 
extracts of the  cell  layers were harvested and  assayed for SFA  as described  in 
Materials and Methods. 
Previous  reports  showed  that  tumor  virus-transformed  fibroblasts  whether 
chicken (3)  or human  (4)  lack SFA on their surface.  The present results show 
that this is true of the glia-glioma system and establish for the first time that 
lack of surface SFA is not confined to fibroblasts transformed in vitro experimen- 
tally by viruses, but is found in at least one type of cells obtained from naturally 
occurring tumors. 
The lack of cell surface SFA in malignant  cells is not  only due to inhibited 
synthesis of this protein in malignant cells, as shown by its presence in intracel- 
lular form in the cytoplasm of glioma cells (Figs. 4-6) and in the culture media of 
virus-transformed fibroblasts (4)  or glioma cells (Table II). The reason for the 
failure of malignant cells to retain SFA on the surface is unknown,  but it may 
have to do with the increased  lability of the cell membrane of malignant cells, 
perhaps resulting from enhanced proteolytic activity on the surface of such cells 
(22). 
Summary 
Fibroblast surface antigen (SFA) is a  high molecular weight protein antigen, 
first shown on the surface of cultured fibroblasts in fibrillar structures.  It is shed 
to  the  extracellular  medium  and  also  present  in  the  circulation  (serum  and 
plasma).  Fibroblasts  transformed  by  tumor  viruses  produce  SFA  but  do  not 
retain it on cell surface. 
In this report we  show that  SFA is also present in cultured  nonestablished 
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guishable.  Glial cells (three different  nonestablished  lines)  contain  more SFA 
per milligram cellular protein than fibroblasts. SFA was located on cell surface 
in fibrillar striae that frequently extended out from the cell body. Fluorescence 
was also found intracellularly in the cytoplasm. 
Malignant gliomas (astrocytomas) established to grow in culture from human 
tumor material produced SFA into the growth medium but had very little (lines 
U-1O5 MG and U-343 MG) or no detectable (lines U-118 MG, U-251 MG, and U- 
343  MG-a)  cell  surface  SFA.  In  cultures  of the  glioma  cells  many  cells,  in 
particular  those  that  appeared  to  be  in  the  telophase  stage,  stained  strongly 
positive for intracellular cytoplasmic SFA. 
These  data  demonstrate  that  similar  to fibroblasts transformed  experimen- 
tally by oncogenic viruses, cells grown from naturally occurring human tumors 
(glioblastomas) produce SFA but lose ability to retain it on cell surface. 
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